Effect of drug Rosuvastatin When given in addition to the existing treatment in patients of skin disease (chronic plaque psoriasis)
Phase 2
Completed
- Conditions
- Health Condition 1: L408- Other psoriasis
- Registration Number
- CTRI/2023/02/049424
- Lead Sponsor
- Pt BD Sharma PGIMS Rohtak
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
1)Patients having Chronic Plaque Psoriasis with Body surface area involvement of 10 percent or greater
2)Patients who are willing to give written informed consent
Exclusion Criteria
1)Patients with present or past history of clinical atherosclerotic cardiovascular disease
2)Patients having deranged Liver Tunction test(LFT)/ Active liver disease(ALD)
3)Patients having clinical features suggestive of myopathy
4)Patients having known allergy to statins
5)Patients who are already on statins
6)Pregnancy and lactation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psoriatic Area and Severity Index(PASI) ScoreTimepoint: Baseline, 4 weeks, 8 weeks and 12 weeks
- Secondary Outcome Measures
Name Time Method Dermatology Life and Quality Index (DLQI)Timepoint: Baseline and 12 weeks;High sensitivity- C reactive protein (hs-CRP)Timepoint: Baseline and 12 weeks;Lipid ProfileTimepoint: Baseline and 12 weeks;PASI 50Timepoint: At the end of 12 weeks